Edwards Lifesciences Corporation (NYSE:EW) Q3 2024 Earnings Conference Call October 24, 2024 5:30 PM ET

Corporate Participants

Mark Wilterding - Senior Vice President & Investor Relations
Bernard Zovighian - Chief Executive Officer
Scott Ullem - Corporate Vice President and Chief Financial Officer
Larry Wood - Corporate Vice President and Group President of TAVR and SSH
Daveen Chopra - Corporate Vice President, TMTT

Conference Call Participants

Larry Biegelsen - Wells Fargo
Vijay Kumar - Evercore ISI
Robbie Marcus - JPMorgan
David Roman - Goldman Sachs
Travis Steed - Bank of America
Matt Taylor - Jefferies
Matt Miksic - Barclays
Joanne Wuensch - Citibank
Danielle Antalffy - UBS
Patrick Wood - Morgan Stanley
Adam Maeder - Piper Sandler

Operator

Greetings and welcome to Edwards Lifesciences Third Quarter 2024 Results Conference Call.

At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. Please note that this conference is being recorded.

I will now turn the conference over to your host, Mark Wilterding, Senior Vice President of Investor Relations. Thank you. You may begin.

Mark Wilterding

Thank you very much, Diego, and welcome everyone. Thank you for joining us this afternoon. With me on today's call is our CEO, Bernard Zovighian, and our CFO, Scott Ullem.

Also joining us for the Q&A portion of the call will be Larry Wood, our Group President of TAVR and Surgical Structural Heart, Daveen Chopra, our Global Leader of TMTT, and Wayne Markowitz, our Global Leader of Surgical Structural Heart.

Just after the close of regular trading, Edwards Lifesciences released third quarter 2024 financial results. During today's call, management will discuss those results included in the press release and accompanying financial statements and then use the remaining time for Q&A.

Please note that management will be making forward-looking statements that are based on estimates, assumptions, and projections. These statements include, but are not limited to, financial guidance and expectations for growth opportunities, strategy, leverage, and integration of our acquisitions, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters, and foreign currency fluctuations. These statements speak only as of the date on which they were made, and Edwards does not undertake any obligation to update them after today.

Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in the press release. Our 2023 Annual Report on Form 10-K and Edwards' other SEC filings, all of which are available on the company's website at edwards.com.